<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643890</url>
  </required_header>
  <id_info>
    <org_study_id>NRGX-GAD-02</org_study_id>
    <nct_id>NCT00643890</nct_id>
  </id_info>
  <brief_title>Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease</brief_title>
  <official_title>Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurologix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurologix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of AAV-GAD gene transfer
      into the subthalamic nucleus (STN) region of the brain. This study involves the treatment of
      subjects with medically refractory Parkinson's disease (PD). The gene transfer product, a
      disabled virus with a gene called GAD, will be infused into the STN bilaterally using
      stereotactic surgical techniques. The overall goal of this approach is to normalize the
      activity of the STN and reduce the motor symptoms of PD.

      Because the change in UPDRS demonstrated a positive outcome, the sham surgery subjects from
      the blinded portion of the study will be invited to crossover into the Open-label Arm portion
      of the study. The Open-label Arm will further evaluate the safety and efficacy of AAV-GAD
      gene transfer into the subthalamic nucleus (STN) region of the brain.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to financial reasons
  </why_stopped>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate a change in UPDRS scores</measure>
  </primary_outcome>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus</intervention_name>
    <description>One-time bilateral administration of rAAV-GAD at 1X10^12 vector genomes in 35 uL.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Parkinson's disease

          -  Duration of disease for at least 5 years

          -  Levodopa responsiveness for at least 12 months

          -  UPDRS Part 3 score ≥ 25 or more in &quot;off&quot; state

        Exclusion Criteria:

          -  Past history of brain surgery for PD

          -  Beck Depression Inventory Score ≥ 20

          -  Any history of cerebral insult or central nervous system infection

          -  Cognitive impairment score &lt; 130 on the Mattis Dementia Rating Scale

          -  Focal neurological deficits

          -  Evidence of significant medical or psychiatric disorders

          -  Secondary Parkinsonism

          -  Atypical Parkinson's disease

          -  History of substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems - Franklin Pointe Medical</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Science Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007 Jun 23;369(9579):2097-105.</citation>
    <PMID>17586305</PMID>
  </reference>
  <reference>
    <citation>Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V, During MJ, Eidelberg D. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19559-64. Epub 2007 Nov 27.</citation>
    <PMID>18042721</PMID>
  </reference>
  <results_reference>
    <citation>LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011 Apr;10(4):309-19. doi: 10.1016/S1474-4422(11)70039-4.</citation>
    <PMID>21419704</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>February 20, 2012</last_update_submitted>
  <last_update_submitted_qc>February 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Keywords:</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>Gene transfer</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Subthalamic nucleus</keyword>
  <keyword>Adeno-associated virus</keyword>
  <keyword>Study placed in the following topic categories:</keyword>
  <keyword>Ganglion Cysts</keyword>
  <keyword>Movement Disorders</keyword>
  <keyword>Parkinson Disease</keyword>
  <keyword>Basal Ganglia Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Parkinsonian Disorders</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Additional relevant MeSH terms:</keyword>
  <keyword>Nervous System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

